Latham & Watkins Advises Erasca on US$550 Million Upsized Public Offering of Common Stock

Erasca, Inc. (Nasdaq: ERAS), a clinical‑stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway‑driven cancers, has announced the pricing of an upsized public offering of 31,428,572 shares of its common stock. The shares of common stock are being sold to the public at a price of US$17.50 per share. All of the shares of common stock to be sold in the public offering are to be sold by Erasca. The gross proceeds to Erasca from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately US$550 million. In addition, Erasca has granted the underwriters a 30‑day option to purchase up to an additional 4,714,285 shares of common stock at the offering price, less underwriting discounts and commissions. The offering is expected to close on July 15, 2026, subject to the satisfaction of customary closing conditions.

Latham & Watkins LLP represents Erasca in the offering, with a corporate team led by San Diego partners Cheston Larson and Matt Bush and counsel Anthony Gostanian, with associates Shelby Harrison and Madeline Hodges.